Abstract: Disclosed is a method for continuous isolation of extracellular vesicles from a biological sample. The method involves filtering the biological sample to obtain a first filtrate of a first predetermined range of particle size, then filtering the first filtrate to obtain a second filtrate of a second predetermined range of particle size, and further filtering the second filtrate to obtain a third filtrate of a third predetermined range of particle size. The third filtrate is mixed with an antibody coated solid substrate to form extracellular vesicles-antibodies conjugate. The extracellular vesicles-antibodies conjugate is isolated from the third filtrate, and selected extracellular vesicles-antibodies conjugate are eluted.

Abstract: The methods of the present invention provide a new diagnostic marker for proliferative conditions and cancers, such as ovarian cancer, endometrial cancer and others. A truncation of MAP1a, CSP80 is an oncoprotein identified as being present in bodily fluids, or contents thereof, of a subject when afflicted with a proliferative condition. The present invention disclosed diagnosis and monitoring of a proliferative condition by detection of CSP80. Additionally, the present invention discloses a targeted treatment of proliferative conditions utilizing CSP80 binding agents, via a variety of delivery vehicles such as nanoparticles.

Abstract: The methods and compositions of the invention provide new diagnostic markers for cancers (e.g., ovarian cancer, PPC, etc.) and other proliferative diseases or conditions such as psoriasis and endometriosis. The methods and compositions of the invention further provide new treatments for such proliferative diseases or conditions.